In this review, we will discuss the molecular mechanisms underlying the oncogenic functions of the Eph receptors family, focusing on the complexity of EphA2 in cancer and on how its unique features should be taken in account for an effective development and use of anti-EphA2 targeted therapies in cancer. This evidence concerns the gene EPHA2 and cancer.